Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Raynauds Disease Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Raynauds Disease Overview | 7 | 1 |
| Raynauds Disease Therapeutics under Development by Companies | 8 | 1 |
| Raynauds Disease Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Raynauds Disease Products under Development by Companies | 12 | 1 |
| Raynauds Disease Companies Involved in Therapeutics Development | 13 | 4 |
| Allergan Plc | 13 | 1 |
| Apricus Biosciences, Inc. | 14 | 1 |
| Covis Pharmaceuticals, Inc. | 15 | 1 |
| Human Stem Cells Institute | 16 | 1 |
| Raynauds Disease Therapeutics Assessment | 17 | 9 |
| Assessment by Monotherapy Products | 17 | 1 |
| Assessment by Target | 18 | 2 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Drug Profiles | 26 | 17 |
| acetylcysteine Drug Profile | 26 | 1 |
| alprostadil Drug Profile | 27 | 7 |
| ELS-140 Drug Profile | 34 | 1 |
| Neovasculgen Drug Profile | 35 | 1 |
| nitroglycerin Drug Profile | 36 | 2 |
| onabotulinumtoxin A Drug Profile | 38 | 5 |
| Raynauds Disease Dormant Projects | 43 | 1 |
| Raynauds Disease Discontinued Products | 44 | 1 |
| Raynauds Disease Product Development Milestones | 45 | 7 |
| Featured News &Press Releases | 45 | 1 |
| Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference | 45 | 1 |
| Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO &Investor Conference, Provide Update on Vitaros | 45 | 1 |
| Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference | 45 | 1 |
| Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May | 45 | 1 |
| Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa | 46 | 1 |
| Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon | 46 | 1 |
| Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa | 47 | 1 |
| Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum | 48 | 1 |
| May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon | 48 | 1 |
| Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana | 48 | 1 |
| May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon | 49 | 1 |
| Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa | 49 | 1 |
| Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma | 50 | 1 |
| Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA | 50 | 2 |
| Appendix | 52 | 2 |
| Methodology | 52 | 1 |
| Coverage | 52 | 1 |
| Secondary Research | 52 | 1 |
| Primary Research | 52 | 1 |
| Expert Panel Validation | 52 | 1 |
| Contact Us | 52 | 1 |
| Disclaimer | 53 | 1 |